Navigating the New Era: A Comprehensive Outlook on Indian and Global Diagnostic Regulations in 2026

Chaitali Parab
Scientist – In Vitro Diagnostics,
Yashraj Biotechnology Ltd.

I. Introduction: The Pulse of Modern Healthcare

Diagnostic tools and technologies serve as the critical backbone of successful healthcare systems, influencing nearly 70% of all healthcare decisions despite accounting for a relatively small percentage of total health expenditures. As technology in the diagnostics sector continues to expand—encompassing in-vitro diagnostics (IVDs), molecular technologies, digital pathology, and Artificial Intelligence (AI)—the need for regulatory systems to be both responsive and proactive has become paramount. For India, this evolution represents a dual imperative: the enhancement of regulatory control must occur in tandem with the fostering of indigenous innovation. Under the "Make in India" initiative, engaging government stakeholders is essential to propel the significance of diagnostics within the national growth agenda. The year 2026 marks a pivotal transition point where India moves from being a volume-driven market to a value-driven innovation hub.

II. India: A Landmark Year for Regulatory Updates

The Indian regulatory landscape is currently undergoing a digital and structural metamorphosis, led by the Central Drugs Standard Control Organization (CDSCO) and the Indian Council of Medical Research (ICMR).

1. Digital Transformation: The Risk Classification Module

A significant milestone is the introduction of the CDSCO's new online risk classification system. This "Medical Devices Online System" is designed specifically for classifying non-IVD medical devices under the Medical Devices Rules, 2017.

a) **Operational Impact**: This system simplifies submissions and provides a formal pathway for devices that have not yet been addressed by existing risk classifications.

b) **Efficiency**: By automating the classification process, the module significantly expedites the overall approval timeline, reducing the "time-to-market" for critical medical technologies.

2. Standardizing Performance for "Make in India"

To ensure that domestic innovations meet global benchmarks, the CDSCO and ICMR have developed comprehensive Draft Standard Evaluation Protocols for 15 IVD product types.

a) **Scope**: These protocols cover high-priority diagnostics, including Dengue, Malaria, and SARS-COV-2.

b) **Mandatory Integration**: While currently available for public comment, these documents will eventually become mandatory for licensing and performance evaluation, providing a clear quality floor for all manufacturers.

c) **Revised Guidance**: The updated Performance Evaluation Reporting (PER) Guidance for IVDs aligns Indian requirements for clinical and analytical performance with international ISO standards. This harmonization is essential for Indian companies looking to export to highly regulated markets like the EU and the US.

3. Support for the Innovation Lifecycle

For domestic innovators, the "MedTech Mitra" IVD Innovators Handbook serves as a vital resource. This joint publication by the CDSCO and ICMR provides a structured approach to the lifecycle stages of an IVD, including quality systems, documentation requirements, and clinical performance evaluation. It acts as a bridge between scientific discovery and regulatory compliance, ensuring that startups and established firms alike can navigate the complexities of the Medical Devices Rules 2017.

4. The Rise of AI and Software as a Medical Device (SaMD)

As AI/ML technologies integrate into clinical workflows, the CDSCO has released draft guidance defining the classification of software used in medical devices. This move is critical for the industry, as it provides a clear regulatory framework for software intended solely for medical purposes, such as diagnostic algorithms used in digital pathology or radiology.

5. Global Regulatory Synchronicity: The 2026 Outlook

Indian manufacturers aiming for the global stage must navigate a complex web of shifting international regulations.

a) **EU IVDR Transition (2017/746):** The European Union continues its phased implementation of the In Vitro Diagnostic Regulation. Key upcoming deadlines include:

b) **Class C (self-declared) devices**: Compliance is required by May 2026.

c) **Class B and A-sterile devices**: Compliance is required by May 2027.

d) **Strategic Requirement**: Manufacturers are encouraged to avoid procrastination regarding EUDAMED database obligations, as transparency and post-market information become essential to regulatory compliance.

e) **UK Regulatory Proposals (MHRA):** The UK's Medicines and Healthcare products Regulatory Agency has proposed measures to enhance access to high-quality devices and foster medtech growth through more efficient conformity assessments and international recognition.

f) **WHO Global Advocacy**: The 5th WHO Global Forum on Medical Devices recently emphasized the need for harmonized regulation and enhanced surveillance systems worldwide to ensure safety and affordability.

6. "Make in India": Driving Innovation and Competitiveness

The "Make in India" initiative has provided a massive impetus to the domestic diagnostics industry, aiming to reduce import dependency and create a self-sustaining ecosystem. This is particularly relevant for specialized reagents and high-grade raw materials—such as antibodies and iPSC-derived cells—which are the "engines" of modern diagnostic kits. The government is actively promoting the manufacture of IVD kits, reagents, and analyzers through the National Medical Devices Policy 2023 and the Production Linked Incentive (PLI) schemes. These efforts, combined with support from the CDSCO and standardized performance criteria, are enhancing both the quality and accessibility of Indian-made diagnostics. For instance, the push for setting up indigenous facilities for rabbit polyclonal antibodies or cell-based platforms illustrates the shift toward localizing the entire supply chain. Along with growing healthcare needs and expanding export markets, "Make in India" is poised to make the diagnostics industry a major driver of national competitiveness.

7. Government Engagement: Strengthening the Ecosystem

Government engagement is fundamental to the evolution of the Indian diagnostics sector. The Ministry of Health and Family Welfare, NITI Aayog, and the Department of Pharmaceuticals serve as key players in developing policies that establish India as a global manufacturing powerhouse. The government also provides active support through public health programs, such as the Free Diagnostics Service Initiative of the National Health Mission. This initiative provides rural citizens with access to critical tests while simultaneously creating a steady demand for quality-assured diagnostics. Over the long term, the combination of policy support, financial incentives, and regulatory reforms will remain the crucial factor in the development of a robust, technology-driven diagnostics industry.

8. Conclusion: A Strategic Commitment

As we look toward the remainder of 2026, the Indian diagnostics industry stands at an inflection point. The synergy between government, industry, and healthcare providers is stronger than ever. By aligning domestic innovation with global regulatory standards, India is not just "making for India"—it is making for the world.